Neurocrine Biosciences, Inc.

Janssen Pharmaceutica Nv

Afraxis Holdings, Inc.

Mannkind Corporation

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fosun Orinove Pharmatech, Inc.

Sova Pharmaceuticals, Inc.

Afraxis, Inc.

Bioblocks Inc.

Mannking Corporation

Warren Stanfield Wade

Martin W Rowbottom

Mi Chen

Timothy Richard Coon

Neil Ashweek

Todd Ewing

Yun-Fei Zhu

Qingping Zeng

Richard B Lowe

John Bruce Patterson

Chen Chen

Zhiqiang Guo

Charles Q Huang

Dongpei Wu

Benedikt K Vollrath

David Alan Campbell

Michael K Ameriks

Fabio C Tucci

Brad M Savall

Jaimie Karyn Rueter

Sergio G Duron

Joseph Pontillo

Jonathan Bryant Grey

Brock T Shireman

Brian Dyck

Junko Tamiya

Wendy Eccles

Srinivas G Rao

Troy Vickers

Nicole Harriott

Graham Beaton

Wanlong Jiang

Willy Moree

Liren Zhao

Nicole Smith

Zoltan Zubovics

Andras Toro

Yun Yang

Yongsheng Chen

Zhipeng Wu

Wesley J Dwight

Sergio G Durón

Brian Ngo Laforteza

Jinghua Yu

Stephen Todd Meyer

Márió Gyuris

Terry Patrick Lebold

Suchitra Ravula

Pablo Garcia-Reynaga

Andrew V Samant

Val S Goodfellow

Justin Chapman

Cynthia B Berry

Gregory Stein

Simon G Sydserff

Yinghong Gao

János Gerencsér

Peter V Pallai

Mingzhu Zhang

Mehrak Kiankarimi

Sarah Clough

Krisztián Biró

Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, Rand Rare as defined herein.

Aryl piperidines as monoacylglycerol lipase modulators

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Compounds which directly inhibit IRE-1&#x3b1; activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

IRE-1&#x3b1; inhibitors

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,  Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators

Fused bicylic pyridine compounds and their use as AMPA receptor modulators

In alternative embodiments the invention provides libraries of compounds, or drugs or drug candidates, manufactured and selected for having a desired property such as a biological or a chemical activity, and methods for making and using them. In one embodiment, the invention provides methods for identifying desirable compounds from very large compound sets using a compound fragment as the query. In alternative embodiments, the invention provides methods of making compounds, and libraries of compounds, using a 'feasible reaction' growth scheme.

Libraries of compounds having desired properties and methods for making and using them

The invention provides compounds which directly inhibit IRE-1&#x3b1; activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

IRE-1alpha inhibitors

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-&#x3b3;-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Cystathionine-&#x3b3;-lyase (CSE) inhibitors

Growing community of inventors

San Diego, CA, United States of America

Warren Stanfield Wade